GenVec has entered into a cooperative research and development agreement with the US Naval Medical Research Center (NMRC) to develop dengue fever vaccines.
Under a contract with the Henry M Jackson Foundation for the Advancement of Military Medicine, GenVec will receive funding for the development and preparation of vaccines related to the research programme.
GenVec will design and manufacture the next generation of vaccine candidates, which will use GenVec’s adenovector technology and be manufactured using GenVec’s proprietary cell line.
The NMRC will take up preclinical animal studies including studies in non-human primates.
GenVec expects to receive approximately $530,000 of revenue following the completion of work under the agreement with the Jackson Foundation in 2011.
Dengue fever, a viral disease spread by mosquitoes, is characterised by fever, headache, rash, eye pain and body aches. It is estimated to affect 50-100 million people each year.